# Baiaojihe GEOFlow

Biogeometry is a generative AI-driven biotech company dedicated to "enabling generative AI to design the next generation of medicines." The company's core product, GeoBiologics, is a new generation AI platform for antibody discovery and protein design. The bottom layer is driven by the self-developed large-scale protein generation model GeoFlow V3 and a high-throughput wet experiment closed-loop platform, covering key aspects such as structural modeling, molecular optimization, de novo design, druggability prediction, and experimental verification. GeoBiologics can generate candidate antibodies, VHHs, small proteins or protein engineering plans based on target structure, target epitope and developability constraints, and continuously iterate the model based on wet experiment results, helping R&D teams shift from traditional "screening candidates" to "designing candidates". The platform can be used for de novo antibody design, antibody affinity optimization, antibody humanization, druggability prediction such as viscosity/expression level/stability/aggregation, as well as engineering of vaccine proteins, enzymes and other functional proteins. Compared with the traditional R&D process that relies on large-scale library screening and repeated trial and error, BIO Geometry improves early hit rates, shortens the discovery cycle, and reduces unnecessary experimental screening through the dry and wet closed loop of "computational design-experimental verification-model learning". The attached case shows that the platform has completed multiple VHH de novo design, IgG design, small protein design, antibody affinity optimization and vaccine protein engineering projects, and in some projects achieved a delivery rhythm of approximately 3 weeks to complete computational design and wet experiment verification.

Biogeometry is a generative AI-driven biotech company dedicated to "enabling generative AI to design the next generation of medicines." The company's core product, GeoBiologics, is a new generation AI platform for antibody discovery and protein design. The bottom layer is driven by the self-developed large-scale protein generation model GeoFlow V3 and a high-throughput wet experiment closed-loop platform, covering key aspects such as structural modeling, molecular optimization, de novo design, druggability prediction, and experimental verification. GeoBiologics can generate candidate antibodies, VHHs, small proteins or protein engineering plans based on target structure, target epitope and developability constraints, and continuously iterate the model based on wet experiment results, helping R&D teams shift from traditional "screening candidates" to "designing candidates". The platform can be used for de novo antibody design, antibody affinity optimization, antibody humanization, druggability prediction such as viscosity/expression level/stability/aggregation, as well as engineering of vaccine proteins, enzymes and other functional proteins. Compared with the traditional R&D process that relies on large-scale library screening and repeated trial and error, BIO Geometry improves early hit rates, shortens the discovery cycle, and reduces unnecessary experimental screening through the dry and wet closed loop of "computational design-experimental verification-model learning". The attached case shows that the platform has completed multiple VHH de novo design, IgG design, small protein design, antibody affinity optimization and vaccine protein engineering projects, and in some projects achieved a delivery rhythm of approximately 3 weeks to complete computational design and wet experiment verification.

Canonical: https://uniquebase.ai/products/UB-D7310
Stable identifier: UB-D7310
Snapshot captured: 2026-10-26T12:23:58.872Z
English updated: 2026-10-26T12:24:19.312Z

## Connected profiles

- [BioGeometry](/companies/UB-C7957)

## Sources

- No source links are available for this profile.